CD19 and B-cell non-Hodgkin lymphoma: CAR T cells targeting the B cell lineage marker CD19 have proven highly successful in generating long-term remission in B cell lymphoma and acute lymphoblastic leukaemia [13], and have the approval of both the Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory Agency (MHRA) for use in these indications.